Justice for Neuralink’s Alleged Animal Testing Victims and Ensure Ethical Human Trials

Target: Robert Califf, Commissioner of the U.S. Food and Drug Administration

Goal: Enforce rigorous ethical standards and accountability in Neuralink’s animal and human testing protocols.

In what many see as a technological breakthrough, Neuralink, co-founded by Elon Musk, has made headlines with the first successful implantation of a wireless brain chip in a human. Yet behind this advancement lies a shadow of ethical concern, with reports alleging that about 1,500 animals, including primates and pigs, were sacrificed in the process since 2018. The public revelation of these figures has ignited a plea for justice and a reassessment of ethical practices in such pioneering medical ventures.

Allegations have surfaced that Neuralink’s initial trials at the UC Davis primate center, and subsequent internal testing, led to the demise of these animals, casting a dark cloud over the company’s research methods. While Neuralink’s endeavors aim to bridge the gap between brain and computer, potentially offering hope for neurological conditions like ALS and Parkinson’s, the reported toll on animal life and concerns over the safety of its methodologies have raised significant ethical and moral questions. These concerns were seemingly validated when the FDA initially denied Neuralink’s application for human trials in 2022, reportedly due to worries about the implant’s threads migrating within the brain.

This situation calls not only for a reflection on the sanctity of life, both animal and human, but also for a demand for heightened oversight and ethical rigor in such groundbreaking trials. It’s imperative that Neuralink’s operations adhere to the strictest ethical standards, ensuring that their path to innovation respects the well-being of all sentient beings involved and that thorough scrutiny is applied to safeguard against future transgressions. Urge a firm commitment to transparency, accountability, and ethical conduct in all future endeavors.


Dear Commissioner Robert Califf,

The pioneering steps taken by Neuralink in the realm of neurotechnology undeniably represent a significant stride towards the future of medical science. However, the loss of approximately 1,500 animals during the company’s initial trials, as reported, casts a grave shadow over these advancements. This distressing figure not only raises concerns about the ethical standards adhered to during the research and development phases but also calls into question the safeguarding of welfare within such cutting-edge medical explorations.

It is crucial that the FDA, as the gatekeeper of medical innovation and ethics, takes a firm stance in ensuring that all endeavors under its purview, especially those as potentially impactful as Neuralink’s, are conducted with the utmost respect for life and ethical integrity. The initial denial and subsequent approval of Neuralink’s human trials by the FDA indicate a recognition of these concerns, yet the public seeks assurance that rigorous oversight and ethical scrutiny are continuously applied.

I implore you to enforce stringent ethical standards and thorough oversight on both animal and human trials conducted by Neuralink and similar entities. It is paramount that these groundbreaking technologies not only pave the way for medical breakthroughs but also exemplify the highest moral and ethical conduct, ensuring that the pursuit of advancement does not come at an unjustifiable cost to sentient life. The world is watching, and it is your responsibility to ensure that this watchful gaze is met with actions that uphold the principles of humanity, ethics, and justice.

[Your Name Here]

Photo credit: TED Conference

One Comment

  1. Donna Leavitt says:

    You want this, the animals do not!Test on yourself and leave the animals alone!

Leave a Reply

Your email address will not be published. Required fields are marked *


312 Signatures

  • Titti Viprödsle
  • Teresa VALENTIN
  • Corbet Stain
  • C Bradley
  • Ricki Newman
  • Barbra Doherty
  • Julie Christopherson
  • Rebecca Martin
  • Kathryn Fenn
  • Brad Sahl
1 of 31123...31
Skip to toolbar